In agreement with the protection from autoimmunity provided by the TYK2:p.Pro1104Ala loss‐of‐function variant, selective TYK2 inhibition has been intensively explored for the treatment of autoimmune diseases and several inhibitors have been developed [16, 19]. This evidence concerns the gene TYK2 and autoimmune disease.